Budesonide · Pulmicort

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (76)
Asthma
NCT05735431 · Eurofarma Laboratorios S.A.
2026-06 – 2027-11 · Moderate Asthma
What this study did
NCT02853578 · Ache Laboratorios Farmaceuticos S.A.
2019-12 – 2020-12 · Asthma
What this study did
NCT03879590 · Universidad Autonoma de Nuevo Leon
2019-05 – 2019-12 · Asthma Chronic, Asthma in Children
What this study did
NCT01266772 · Medical University of Lodz
2011-01 – 2013-12 · Bronchial Asthma
What this study did
NCT01360021 · AstraZeneca
2011-11 – 2012-08 · Asthma
What this study did
NCT01676987 · Ache Laboratorios Farmaceuticos S.A.
2009-04 – 2011-06 · Asthma
What this study did
NCT00675584 · Milton S. Hershey Medical Center
2008-08 – 2010-07 · Asthma
What this study did
NCT00588406 · Northwell Health
2007-09 – 2009-12 · Asthma
What this study did
NCT00419952 · AstraZeneca
2007-02 – 2009-11 · Asthma
What this study did
NCT00855959 · AstraZeneca
2009-02 – 2009-08 · Asthma
What this study did
NCT00462592 · Hamilton Health Sciences Corporation
2007-03 – 2009-06 · Asthma
What this study did
NCT00509028 · AstraZeneca
2006-12 – 2008-10 · Asthma
What this study did
NCT00536731 · AstraZeneca
2007-09 – 2008-04 · Bronchial Asthma
What this study did
NCT00449501 · AstraZeneca
2007-03 – 2007-11 · Asthma
What this study did
NCT00504062 · AstraZeneca
2006-10 – 2007-10 · Asthma
What this study did
NCT00449527 · AstraZeneca
2007-03 – 2007-08 · Asthma
What this study did
NCT00259766 · AstraZeneca
2004-04 – 2007-05 · Asthma
What this study did
NCT00232648 · AstraZeneca
2004-01 – 2006-11 · Asthma
What this study did
NCT00642122 · AstraZeneca
2003-04 – 2004-12 · Asthma
What this study did
NCT00646321 · AstraZeneca
2003-04 – 2004-08 · Asthma
What this study did
NCT00652392 · AstraZeneca
2003-04 – 2004-06 · Asthma
What this study did
NCT00652002 · AstraZeneca
2002-07 – 2004-01 · Asthma
What this study did
NCT00651547 · AstraZeneca
2002-07 – 2003-10 · Asthma
What this study did
NCT00646529 · AstraZeneca
2002-07 – 2003-10 · Asthma
What this study did
NCT00651651 · AstraZeneca
2002-08 – 2003-09 · Asthma
What this study did
Other / comorbidity
NCT05509933 · Henry Ford Health System
2022-11-09 – 2027-12-30 · Engraftment Syndrome
What this study did
NCT04545866 · NICHD Neonatal Research Network
2021-04-01 – 2026-12-17 · Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
What this study did
NCT04862377 · Hospital Clinic of Barcelona
2021-10-01 – 2026-04-01 · Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant, Prematurity
What this study did
NCT07763119 · Khyber Teaching Hospital
2025-11-28 – 2026-04-01 · Meconium Aspiration Syndrome
What this study did
NCT05325489 · Second Xiangya Hospital of Central South University
2022-04 – 2024-09 · Snoring, Mouth Breathing
What this study did
NCT04727424 · Cardresearch
2021-01-19 – 2024-07-01 · Covid19, SARS-Associated Coronavirus
What this study did
NCT03323866 · Université de Sherbrooke
2017-05-01 – 2022-08-01 · Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis
What this study did
NCT03245840 · Shire
2017-10-05 – 2022-04-26 · Eosinophilic Esophagitis (EoE)
What this study did
NCT03412682 · Ferring Pharmaceuticals
2018-03-02 – 2020-05-26 · Colitis, Ulcerative
What this study did
NCT02142634 · Dr. Falk Pharma GmbH
2014-05 – 2020-02 · Incomplete Microscopic Colitis
What this study did
NCT02972866 · Eurofarma Laboratorios S.A.
2016-06 – 2019-11 · Rhinitis, Allergic, Perennial
What this study did
NCT00746486 · Dr. Falk Pharma GmbH
2009-02 – 2019-10 · Primary Biliary Cirrhosis
What this study did
NCT03755557 · Marinomed Biotech AG
2018-11-19 – 2019-04-05 · Allergic Rhinitis, Allergic Conjunctivitis, Hayfever
What this study did
NCT02605837 · Shire
2015-12-07 – 2019-02-15 · Eosinophilic Esophagitis (EoE)
What this study did
Phase 2/3 (12)
Asthma
NCT01524198 · King Saud University
2010-11 – 2012-04 · Status Asthmaticus
What this study did
NCT01269437 · NovaMed Pharmaceuticals Inc.
2010-12 – 2011-10 · Asthma
What this study did
Other / comorbidity
NCT06719622 · Medical University of Warsaw
2024-07-30 – 2027-12-31 · Crohn Disease (CD)
What this study did
NCT05931744 · Kafrelsheikh University
2021-05-01 – 2023-02-01 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT04027322 · Oman Medical Speciality Board
2019-06-01 – 2022-05-30 · Acute Pharyngitis
What this study did
NCT01907204 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2013-07 – 2014-01 · Sinusitis
What this study did
NCT02024659 · Beijing Tongren Hospital
2010-09 – 2014-01 · Nasal Polyps
What this study did
NCT00728481 · Mayo Clinic
2008-05 – 2010-12 · Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
What this study did
NCT00633919 · ALK-Abelló A/S
2006-07 – 2009-02 · Allergy
What this study did
NCT00838214 · Dr. Falk Pharma GmbH
2001-03 – 2008-12 · Autoimmune Hepatitis
What this study did
NCT00217022 · Mayo Clinic
2003-06 – 2008-02 · Lymphocytic Colitis, Diarrhea
What this study did
NCT00175747 · University of British Columbia
2000-01 – 2002-12 · Lung Cancer
What this study did
Phase 2 (42)
Asthma
NCT06482294 · Università degli Studi di Ferrara
2024-06-18 – 2025-07-01 · Asthma
What this study did
NCT02991859 · GlaxoSmithKline
2017-02-09 – 2018-12-20 · Asthma
What this study did
NCT02105012 · Pearl Therapeutics, Inc.
2014-04-01 – 2015-09-04 · Asthma
What this study did
NCT01136382 · AstraZeneca
2010-07 – 2013-04 · Asthma
What this study did
NCT01200108 · Activaero GmbH
2010-03 – 2011-11 · Asthma
What this study did
NCT00989833 · AstraZeneca
2009-09 – 2010-07 · Exercise Induced Asthma
What this study did
NCT00995904 · Allergan
2009-09 – 2009-11 · Asthma
What this study did
NCT00554970 · Allergan
2007-11 – 2008-03 · Asthma
What this study did
Other / comorbidity
NCT06860542 · AHS Cancer Control Alberta
2026-02-10 – 2030-12-01 · Pneumonitis, Immune-related Adverse Event
What this study did
NCT04918953 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-06-02 – 2026-12-30 · Outcome
What this study did
NCT04294641 · National Cancer Institute (NCI)
2021-05-10 – 2024-10-01 · Chronic GVHD
What this study did
NCT04422275 · Washington University School of Medicine
2021-06-01 – 2023-12-31 · Anosmia
What this study did
NCT05055414 · Korea United Pharm. Inc.
2021-11-01 – 2022-11-01 · Coronavirus Infection
What this study did
NCT02833480 · University of British Columbia
2015-02 – 2021-06 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03716115 · Queen Mary University of London
2020-05-04 – 2021-04-27 · Severe Acute Malnutrition
What this study did
NCT02400476 · Puma Biotechnology, Inc.
2015-02 – 2021-04-22 · Early Stage HER2+ Breast Cancer
What this study did
NCT04416399 · University of Oxford
2020-07-16 – 2021-01-12 · Coronavirus Infection
What this study did
NCT01895075 · Dr. Michael Dunn
2019-01-01 – 2020-09-01 · Bronchopulmonary Dysplasia
What this study did
NCT04064684 · The University of Texas Health Science Center, Houston
2020-02-04 – 2020-03-30 · Acute Respiratory Distress Syndrome
What this study did
NCT02991768 · University of Kansas Medical Center
2017-01-27 – 2019-04-26 · Diarrhea
What this study did
NCT01821898 · Baylor College of Medicine
2013-07-09 – 2018-09-24 · Eosinophilic Esophagitis
What this study did
NCT02550418 · Dr. Falk Pharma GmbH
2015-10 – 2017-03 · Colitis, Ulcerative
What this study did
NCT02425813 · Wake Forest University Health Sciences
2015-10 – 2016-07 · Acute Graft Versus Host Disease, Intestinal Graft Versus Host Disease
What this study did
NCT01783821 · Mayo Clinic
2013-07 – 2015-12 · Acute Respiratory Distress Syndrome (ARDS)
What this study did
NCT01966783 · Dr. Falk Pharma GmbH
2013-09 – 2015-08 · Proctitis
What this study did
NCT01642212 · Shire
2012-07-23 – 2014-10-30 · Eosinophilic Esophagitis (EoE)
What this study did
NCT02280616 · Dr. Falk Pharma GmbH
2011-06 – 2014-05 · Eosinophilic Esophagitis
What this study did
NCT01268215 · East Carolina University
2010-07 – 2013-12 · Bronchopulmonary Dysplasia
What this study did
NCT01814618 · University of North Carolina, Chapel Hill
2013-03 – 2013-11 · Olfaction Disorders, Sinusitis, Paranasal Sinus Diseases
What this study did
NCT00828230 · Dr. Falk Pharma GmbH
2008-09 – 2011-10 · Radiation Proctitis
What this study did
NCT01023516 · AstraZeneca
2009-11 – 2010-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00762073 · Shire
2009-01-08 – 2010-04-02 · Eosinophilic Esophagitis (EoE)
What this study did
NCT00805285 · University of Maryland, Baltimore
2008-10 – 2010-03 · Inflammatory Bowel Disease, Ulcerative Colitis
What this study did
NCT00638456 · Ranjan Dohil
2008-02 – 2009-09 · Eosinophilic Esophagitis
What this study did
NCT00634413 · Pulmagen Therapeutics
2008-02 – 2009-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00271349 · Swiss EE Study Group
2005-12 – 2008-12 · Eosinophilic Esophagitis
What this study did
NCT00321893 · National Cancer Institute (NCI)
2006-01 – 2008-09 · Lung Cancer
What this study did
NCT00005880 · British Columbia Cancer Agency
started 2000-07 · Lung Cancer
What this study did
NCT00938613 · Ligand Pharmaceuticals
2007-02 – 2007-04 · Seasonal Allergic Rhinitis
What this study did
NCT00117182 · Syntara
2005-07 – 2006-08 · Lung Diseases, Obstructive
What this study did
NCT00641693 · AstraZeneca
2004-04 – 2005-05 · Allergic Rhinitis
What this study did
NCT00641979 · AstraZeneca
2002-04 – 2002-08 · Seasonal Allergic Rhinitis
What this study did
Phase 1/2 (8)
Other / comorbidity
Little Lungs Studynot yet recruiting
NCT06855043 · University of Wisconsin, Madison
2027-02 – 2029-08 · Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
What this study did
NCT03250975 · Vanderbilt University Medical Center
2017-08-19 – 2026-12-30 · Intubation Complication
What this study did
Nebulized Nasal Steroidsnot yet recruiting
NCT07270302 · Washington University School of Medicine
2025-12 – 2026-05 · Chronic Rhinosinusitis
What this study did
NCT06657079 · Damanhour University
2024-05-01 – 2025-01-01 · ARDS, Prevention and Control
What this study did
NCT01955980 · Pari Pharma GmbH
2015-10-27 – 2021-07-29 · Rhinosinusitis
What this study did
NCT01946711 · Pari Pharma GmbH
2013-08-28 – 2021-06-21 · Rhinosinusitis, Chronic Polyposis
What this study did
NCT04019106 · University of Manitoba
2019-10-15 – 2021-01-15 · Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant
What this study did
NCT02907593 · Cynthia McEvoy
2016-09 – 2018-04 · Bronchopulmonary Dysplasia (BPD)
What this study did
Phase 1 (26)
Asthma
NCT04016220 · University of Monastir
2019-05-20 – 2020-05-20 · Acute Asthma
What this study did
NCT04494321 · Intech Biopharm Ltd.
2017-06-19 – 2017-11-17 · Asthma, COPD
What this study did
NCT02187445 · Vanderbilt University
2014-06 – 2017-02-13 · Sickle Cell Disease, Asthma, Acute Chest Syndrome
What this study did
NCT02850484 · Intech Biopharm Ltd.
2016-03 – 2016-05 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01511302 · Revalesio Corporation
2012-06 – 2013-05 · Asthma
What this study did
NCT02165046 · Intech Biopharm Ltd.
2012-02 – 2012-08 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00595153 · University of California, San Francisco
2007-04 – 2011-06 · Asthma
What this study did
NCT00627679 · Allergan
2005-12 – 2006-05 · Asthma
What this study did
Other / comorbidity
NCT07081399 · Damanhour University
2024-08-08 – 2025-08 · Dysphagia, Dysphagia Rehabilitation
What this study did
NCT06367881 · Ain Shams University
2022-08-18 – 2024-10 · Neonatal Respiratory Distress Syndrome, Inflammatory Response, Premature Lungs, Neutrophil Extracellular Trap Formation, Preterm Birth
What this study did
NCT06595121 · Unither Pharmaceuticals, France
2024-08-13 – 2024-09-16 · Healthy
What this study did
NCT06268301 · Takeda
2023-02-06 – 2023-02-20 · Healthy Volunteers
What this study did
NCT04476628 · St. Paul's Hospital, Canada
2021-02-01 – 2022-02-28 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT05148312 · Aquilon Pharmaceuticals S.A.
2021-11-12 – 2022-02-21 · Pharmacokinetics
What this study did
NCT04267042 · St. Paul's Hospital, Canada
2020-02-03 – 2021-02-03 · Chronic Rhinosinusitis With Nasal Polyps, Allergic Fungal Sinusitis
What this study did
NCT01950507 · National Institutes of Health Clinical Center (CC)
2014-02-20 – 2020-02-26 · Stem Cell Transplantation, Graft vs Host Disease
What this study did
NCT03934333 · AstraZeneca
2019-05-16 – 2019-09-10 · Relative Bioavailability
What this study did
NCT04097613 · St. Paul's Hospital, Canada
2017-07-28 – 2019-08-31 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT03436225 · Assiut University
2019-02 – 2019-03 · Bronchiolitis; Respiratory Syncytial Virus
What this study did
NCT05429775 · Sandoz
2018-12-26 – 2019-01-29 · Healthy Volunteers
What this study did
NCT02811016 · Salzburger Landeskliniken
2016-06 – 2016-10 · Acute Mountain Sickness
What this study did
NCT04077892 · Beijing Tongren Hospital
2016-06-01 – 2016-09-30 · Allergic Rhinitis
What this study did
NCT02800824 · Padagis LLC
est. completion 2016-06 · Healthy
What this study did
NCT02593500 · Reig Jofre Group
2014-04 – 2014-05 · Allergy
What this study did
NCT00975754 · AstraZeneca
2009-09 – 2009-11 · Healthy Volunteers
What this study did
NCT00004842 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1997-05 – 1999-04 · Cholangitis, Sclerosing, Liver Cirrhosis, Biliary
What this study did
Phase 4 (61)
Asthma
NCT03369847 · New York City Health and Hospitals Corporation
2017-09-10 – 2019-06-30 · Asthma, Pediatric ALL
What this study did
NCT03034005 · Bispebjerg Hospital
2017-03-27 – 2019-02-28 · Asthma
What this study did
NCT02771717 · University of Nottingham
2016-05 – 2018-07 · Asthma
What this study did
NCT01520688 · West Penn Allegheny Health System
2012-02 – 2016-02 · Asthma
What this study did
NCT01912872 · Novartis Pharmaceuticals
2013-11-11 – 2016-01-08 · Severe IgE-mediated Asthma
What this study did
NCT02233803 · GlaxoSmithKline
2014-11-14 – 2015-12-11 · Asthma
What this study did
NCT01070888 · Boston Children's Hospital
2010-02 – 2014-04 · Exercise Induced Asthma
What this study did
NCT00661973 · Imperial College London
2008-04 – 2011-03 · Asthma
What this study did
NCT01340118 · Chungbuk National University
2010-05 – 2010-07 · Asthma
What this study did
NCT00624429 · Phoenix Children's Hospital
2008-03 – 2010-01 · Asthma
What this study did
NCT00733473 · Kecioren Education and Training Hospital
2007-09 – 2010-01 · Asthma, Acute Asthma
What this study did
NCT00733317 · Kecioren Education and Training Hospital
2007-09 – 2009-12 · Asthma, Acute Asthma
What this study did
NCT00702325 · AstraZeneca
2008-06 – 2009-09 · Asthma
What this study did
NCT00584636 · Phoenix Children's Hospital
2007-10 – 2009-03 · Asthma
What this study did
NCT00522782 · AAADRS Clinical Research Center
2007-08 – 2009-01 · Asthma
What this study did
NCT00189436 · Deborah Gentile
2003-03 – 2009-01 · Asthma
What this study did
NCT00716963 · Hamilton Health Sciences Corporation
2008-07 – 2008-12 · Mild Intermittent Asthma
What this study did
NCT00487773 · Medical University of Lodz
2007-09 – 2008-09 · Asthma
What this study did
NCT00380484 · Children´s Clinic, Randers
2006-09 – 2008-02 · Asthma
What this study did
NCT00393367 · Children's Hospital of Philadelphia
2006-12 – 2007-11 · Asthma, Acute Asthma, Reactive Airway Exacerbation
What this study did
NCT00490243 · Medical University of Lodz
2003-07 – 2006-10 · Asthma
What this study did
NCT00228475 · AstraZeneca
2004-09 – 2005-10 · Asthma
What this study did
NCT00641472 · AstraZeneca
2002-10 – 2005-02 · Asthma
What this study did
NCT00234390 · AstraZeneca
1998-11 – 2004-12 · Asthma
What this study did
NCT00641446 · AstraZeneca
2001-10 – 2003-10 · Asthma
What this study did
NCT00641914 · AstraZeneca
1996-10 – 2003-02 · Asthma
What this study did
Other / comorbidity
NCT06334575 · Maria Joyera Rodríguez
2025-02-12 – 2027-12 · Chronic Obstructive Pulmonary Disease
What this study did
NCT06209047 · Assiut University
2023-10-15 – 2027-02-01 · Bronchiectasis With Acute Exacerbation
What this study did
NCT07491991 · Qianfoshan Hospital
2025-03-02 – 2026-03-01 · Postoperative Pain, NEBULIZATION, Thyroid Surgery
What this study did
NCT03615742 · University of British Columbia
2018-12-01 – 2025-12-31 · Exposure to Pollution, Glucocorticoid Resistance
What this study did
NCT07725575 · Universitas Indonesia
2024-11-01 – 2025-06-01 · Bronchopulmonary Dysplasia (BPD)
What this study did
NCT05364385 · University of Arizona
2019-12-02 – 2024-12 · Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
What this study did
NCT06858423 · Benha University
2023-08-15 – 2024-05-31 · Nasal Allergy
What this study did
NCT05444543 · University Hospitals Cleveland Medical Center
2021-11-17 – 2023-10-13 · Eosinophilic Esophagitis
What this study did
NCT05474924 · Kafrelsheikh University
2022-08-01 – 2022-12-01 · CRS, Polyp, Nasal
What this study did
NCT03275415 · Taipei Medical University
2019-07-01 – 2022-06-30 · Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
What this study did
NCT03315052 · Montefiore Medical Center
2019-01 – 2022-01 · Acute Cellular Graft Rejection, Liver Transplant Rejection
What this study did
NCT03866538 · Mayo Clinic
2019-09-10 – 2021-10-19 · Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue, Autoimmune Enteropathy
What this study did
NCT04355637 · Sara Varea
2020-04-21 – 2021-06-30 · Coronavirus Infection
What this study did
NCT03219866 · Wake Forest University Health Sciences
2017-10-03 – 2020-04-01 · COPD, COPD Exacerbation
What this study did
NCT03521063 · Hospital Central "Dr. Ignacio Morones Prieto"
2018-01-01 – 2019-12-31 · Bronchopulmonary Dysplasia, Infant,Premature, Respiratory Distress Syndrome
What this study did
NCT04520230 · Tanta University
2014-10-31 – 2019-12-31 · COPD
What this study did
NCT02019758 · University of North Carolina, Chapel Hill
2015-01-01 – 2019-04 · Eosinophilic Esophagitis
What this study did
NCT02357277 · Columbia University
2015-03 – 2018-11 · Osteoporosis
What this study did
NCT02002715 · The First Affiliated Hospital of Guangzhou Medical University
2008-03 – 2018-05 · Eosinophilic Bronchitis
What this study did
NCT02696850 · Washington University School of Medicine
2016-01-01 – 2017-04-13 · Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
What this study did
NCT03394222 · Fujian Medical University Union Hospital
2016-07 – 2017-04 · Lung Cancer
What this study did
NCT02504801 · Xiuyi Zhi
2015-07 – 2016-10 · Post Operative Complication, Pulmonary, Lung Cancer, COPD
What this study did
NCT02055352 · Novartis Pharmaceuticals
2014-05-30 – 2016-01-26 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01253473 · National Jewish Health
2012-04 – 2016-01 · Pulmonary Disease, Chronic Obstructive
What this study did
Early phase / not applicable (42)
Asthma
NCT06080945 · Shaoxing Maternity and Child Health Care Hospital
2022-01-04 – 2024-06-30 · Asthma in Children
What this study did
NCT05904002 · Cairo University
2020-09-20 – 2022-02-15 · Asthmatic, Pregnant With Complication
What this study did
NCT03504527 · Huashan Hospital
2018-05-01 – 2019-05-01 · Asthma-COPD Overlap
What this study did
NCT03175926 · University Hospital, Bordeaux
2017-12-01 – 2018-09-01 · Asthma
What this study did
NCT01973751 · Tongji Hospital
2013-11 – 2016-07 · Asthma
What this study did
NCT01484691 · University of California, San Francisco
2012-01 – 2015-07 · Asthma
What this study did
NCT00859274 · Kuopio University Hospital
2009-03 – 2013-10 · Asthma
What this study did
NCT01179152 · Meir Medical Center
2010-09 – 2012-10 · Asthma Exacerbation
What this study did
NCT01219738 · University of Miami
2008-07 – 2012-08 · Asthma
What this study did
NCT00706446 · Brigham and Women's Hospital
2008-06 – 2011-09 · Asthma
What this study did
NCT01219036 · Liam Heaney
2008-10 – 2011-07 · Asthma
What this study did
NCT01218399 · Stanford University
2009-09 – 2010-07 · Asthma
What this study did
NCT01055041 · Government Medical College, Bhavnagar
2008-12 – 2009-07 · Moderate to Severe Persistent Bronchial Asthma
What this study did
NCT00388739 · Baylor College of Medicine
2006-11-01 – 2006-11-01 · Asthma
What this study did
NCT00319488 · National Heart, Lung, and Blood Institute (NHLBI)
2004-02 – 2006-11 · Asthma, Lung Diseases
What this study did
NCT00159263 · Imperial College London
2004-11 – 2006-11 · Asthma
What this study did
NCT00233584 · AstraZeneca
2001-07 – 2006-06 · Asthma
What this study did
Other / comorbidity
NCT07386873 · Peking University Third Hospital
2026-09-25 – 2028-12-31 · Chronic Rhinosinusitis (CRS), Olfactory Dysfunction
What this study did
NCT05839756 · Mansoura University
2023-05-03 – 2028-06-30 · Stridor, Larynx Edema
What this study did
NCT07877519 · China National Center for Cardiovascular Diseases
2026-06-01 – 2028-06 · Paroxysmal Atrial Fibrillation
What this study did
NCT07684105 · Centre Hospitalier Universitaire de Nice
2026-07-01 – 2027-06-30 · Recessive Dystrophic Epidermolysis Bullosa, Dysphagia, Esophageal Stenosis
What this study did
NCT05791487 · Wolfson Medical Center
2023-12-01 – 2026-09-01 · Ulcerative Colitis, Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
What this study did
NCT07528820 · St. Paul's Sinus Centre
2026-07-01 – 2026-08-01 · CRSwNP, Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis
What this study did
NCT05534685 · Coordinación de Investigación en Salud, Mexico
2022-09-20 – 2023-07-20 · Respiratory Tract Diseases
What this study did
NCT04675463 · ShiYue Li
2020-12-30 – 2023-06-30 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03999008 · St. Justine's Hospital
2020-06-01 – 2023-06-01 · Esophageal Atresia, Anastomotic Stenosis
What this study did
NCT03584178 · St. Paul's Hospital, Canada
2018-09-05 – 2021-12-25 · Sinusitis
What this study did
NCT04561687 · Shiraz University of Medical Sciences
2020-01-16 – 2021-12-15 · Allergic Rhinitis
What this study did
NCT04291118 · St. Paul's Hospital, Canada
2020-02-10 – 2021-10-01 · Chronic Sinusitis
What this study did
NCT02715167 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2016-03 – 2017-12 · Healthy
What this study did
NCT02562924 · University of Vermont Medical Center
2015-11 – 2017-12 · Chronic Sinusitis, Nasal Polyposis
What this study did
NCT02013115 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2015-01-01 – 2017-10-30 · Respiratory Distress Syndrome
What this study did
NCT02056379 · Hospital Israelita Albert Einstein
2014-03 – 2016-03 · Stridor
What this study did
NCT02194062 · Yale University
2015-01 – 2015-08 · Sinusitis, Nasal Polyps
What this study did
NCT00184171 · Norwegian University of Science and Technology
2001-11 – 2014-10 · Colitis
What this study did
NCT01786070 · Isfahan University of Medical Sciences
2011-03 – 2014-03 · Respiratory Sounds
What this study did
NCT02125851 · Walter Reed National Military Medical Center
2014-01 – 2014-02 · Eosinophilic Esophagitis
What this study did
NCT01373528 · Ottawa Hospital Research Institute
2010-12 – 2012-05 · Chronic Rhinosinusitis
What this study did
NCT00961233 · University of North Carolina, Chapel Hill
2009-10 – 2011-11 · Eosinophilic Esophagitis
What this study did
NCT00587119 · Mayo Clinic
2007-12 – 2009-07 · Primary Biliary Cirrhosis, Autoimmune Hepatitis
What this study did
NCT00728715 · Hospital General de Requena
2004-01 – 2005-01 · Bronchiectasis
What this study did
Used as active comparator (40)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Asthma
NCT04215848 · Hat Yai Medical Education Center
2020-04-01 – 2022-05-30 · Asthma
What this study did
NCT02149199 · AstraZeneca
2014-07-07 – 2017-08-02 · Asthma
What this study did
NCT02725242 · Hat Yai Medical Education Center
2016-03 – 2016-12 · Asthma
What this study did
NCT01444430 · AstraZeneca
2011-12 – 2015-10 · Asthma
What this study did
NCT01687283 · GlaxoSmithKline
2012-09-27 – 2013-11-07 · Asthma
What this study did
NCT00442117 · Organon and Co
2007-06 – 2009-07 · Asthma
What this study did
Phase 2 (16)
Asthma
NCT07807007 · Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
2025-11-21 – 2026-08-17 · Asthma
What this study did
NCT06940700 · Guangdong Hengrui Pharmaceutical Co., Ltd
2025-04 – 2025-12 · Asthma
What this study did
NCT01136655 · AstraZeneca
2010-09 – 2011-12 · Asthma
What this study did
NCT01225549 · AstraZeneca
2010-11 – 2011-12 · Asthma
What this study did
NCT01293734 · Liaoning University of Traditional Chinese Medicine
2008-12 – 2011-02 · Bronchial Asthma
What this study did
NCT00327808 · Syntara
2006-05 – 2007-03 · Asthma
What this study did
Other / comorbidity
NCT07499791 · Beijing Tongren Hospital
2026-05-01 – 2027-12-01 · Chronic Dacryocystitis
What this study did
NCT05915104 · University of Calgary
2024-03-21 – 2026-12 · Microscopic Colitis
What this study did
NCT05269017 · Menoufia University
2022-06 – 2023-03 · Parosmia
What this study did
NCT05269030 · Menoufia University
2022-07 – 2023-03 · Parosmia
What this study did
NCT04163978 · Sanotize Research and Development corp.
2019-10-27 – 2022-05-03 · Chronic Sinusitis
What this study did
NCT01783106 · Royal Liverpool University Hospital
2014-02-01 – 2019-09-30 · Crohn's Disease
What this study did
NCT02986321 · Chiesi Farmaceutici S.p.A.
2016-12-15 – 2018-01-09 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01555099 · AstraZeneca
2012-04 – 2013-04 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00483743 · Syntara
2007-11 – 2008-12 · Copd Bronchitis
What this study did
Phase 1/2 (2)
Asthma
NCT04933383 · Aquilon Pharmaceuticals S.A.
2021-07-23 – 2023-01-31 · Asthma
What this study did
Other / comorbidity
NCT01405339 · St. Paul's Hospital, Canada
2011-08 – 2014-01 · Chronic Rhinosinusitis
What this study did
Phase 1 (3)
Asthma
NCT04848662 · Bond Avillion 2 Development LP
2021-05-06 – 2021-07-08 · Asthma
What this study did
NCT04032834 · Vectura Limited
2017-02-20 – 2017-05-22 · Asthma
What this study did
Phase 4 (7)
Asthma
NCT05152355 · Intech Biopharm Ltd.
2019-04-22 – 2021-05-09 · Asthma
What this study did
NCT00092092 · Organon and Co
2002-10 – 2004-06 · Asthma, Bronchial
What this study did
Other / comorbidity
NCT07675252 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-08-01 – 2027-06-30 · Acute Wheezing Disorders in Infants Aged 0 to 24 Months
What this study did
NCT06158893 · Assiut University
2024-08 – 2025-10 · Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy
What this study did
NCT02526758 · Zhujiang Hospital
2015-04 – 2016-05 · Pulmonary Disease,Chronic Obstructive;
What this study did
NCT01712854 · Columbia University
2012-03 – 2012-09 · Chronic Obstructive Lung Disease
What this study did
NCT00554710 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
2001-05 – 2004-01 · Crohn's Disease
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT06890260 · Pengfei Qiu
2025-04-11 – 2027-12-31 · Allergic Rhinitis (Disorder), Electroacupuncture, Microneedle Knife
What this study did
NCT06837051 · Peking University Third Hospital
2025-03-14 – 2027-03-14 · Olfactory Dysfunction, Chronic Rhinosinusitis
What this study did
Studied as part of a combination product (134)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (56)
Asthma
NCT06429475 · University of KwaZulu
2024-06-06 – 2028-12-31 · Asthma
What this study did
NCT07318350 · Eurofarma Laboratorios S.A.
2026-10 – 2028-09 · Moderate Asthma
What this study did
NCT06471257 · AstraZeneca
2024-06-17 – 2027-10-04 · Asthma
What this study did
NCT06895460 · The First Affiliated Hospital with Nanjing Medical University
2025-06-20 – 2027-09-30 · Bronchial Asthma
What this study did
NCT05831566 · Franciscus Gasthuis
2023-01-31 – 2026-04-30 · Asthma
What this study did
NCT07790159 · Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
2024-02-21 – 2024-11-07 · Asthma
What this study did
NCT04191434 · EMS
2022-07-22 – 2023-10 · Asthma
What this study did
NCT04191447 · EMS
2022-07-22 – 2023-10 · Asthma
What this study did
NCT05322707 · Cipla Ltd.
2022-04-15 – 2023-08-29 · Asthma
What this study did
NCT04705727 · Centre Hospitalier Intercommunal Creteil
2021-08-23 – 2023-06-23 · Asthma in Children
What this study did
NCT03769090 · Bond Avillion 2 Development LP
2018-12-13 – 2022-02-07 · Asthma
What this study did
NCT03468790 · Shanghai Biomabs Pharmaceutical Co., Ltd.
2018-05-09 – 2021-03-09 · Asthma, Allergic
What this study did
NCT04234464 · Bond Avillion 2 Development LP
2020-01-15 – 2020-08-28 · Exercise Induced Bronchospasm
What this study did
NCT04607629 · AO GENERIUM
2018-06-20 – 2019-12-13 · Bronchial Asthma
What this study did
NCT03015259 · Kindeva Drug Delivery
2016-12-29 – 2018-02-08 · Asthma
What this study did
NCT02308098 · Orion Corporation, Orion Pharma
2014-12 – 2015-06 · Asthma
What this study did
NCT02062463 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-05-28 – 2015-03-13 · Asthma
What this study did
NCT01803555 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-07-04 – 2014-03-20 · Asthma
What this study did
NCT00849095 · Università degli Studi di Ferrara
2009-04 – 2013-05 · Asthma
What this study did
NCT01167010 · Eurofarma Laboratorios S.A.
2011-04 – 2012-02 · Asthma
What this study did
NCT01001364 · Eurofarma Laboratorios S.A.
2010-02 – 2011-04 · ASTHMA
What this study did
NCT00691951 · Laval University
— · Asthma
What this study did
NCT00385593 · AstraZeneca
2006-09 – 2008-10 · Asthma, Bronchial
What this study did
NCT00536913 · AstraZeneca
2007-09 – 2008-02 · Asthma
What this study did
NCT00255255 · AstraZeneca
2005-11 – 2007-06 · Asthma
What this study did
NCT00326053 · AstraZeneca
2006-05 – 2007-05 · Asthma
What this study did
NCT00252824 · AstraZeneca
2005-07 – 2006-12 · Asthma
What this study did
NCT00319306 · AstraZeneca
2005-09 – 2006-12 · Asthma
What this study did
NCT00235911 · AstraZeneca
2003-09 – 2006-12 · Asthma
What this study did
NCT00290264 · AstraZeneca
2004-12 – 2006-08 · Asthma
What this study did
NCT00288379 · AstraZeneca
2004-10 – 2006-05 · Asthma
What this study did
NCT00238784 · AstraZeneca
2004-05 – 2005-10 · Asthma
What this study did
NCT00646516 · AstraZeneca
2003-10 – 2005-02 · Mild or Moderate Asthma
What this study did
NCT00646594 · AstraZeneca
2003-11 – 2005-01 · Asthma
What this study did
NCT00651768 · AstraZeneca
2003-08 – 2005-01 · Asthma
What this study did
NCT00646620 · AstraZeneca
2003-04 – 2003-09 · Asthma
What this study did
NCT00646009 · AstraZeneca
2003-03 – 2003-08 · Asthma
What this study did
Other / comorbidity
NCT04193878 · Stanford University
2020-06-01 – 2025-07-22 · Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
What this study did
NCT03197818 · Chiesi Farmaceutici S.p.A.
2016-12-14 – 2020-05-26 · COPD (Chronic Obstructive Pulmonary Disease)
What this study did
NCT02477397 · University Medical Center Groningen
2015-05-01 – 2019-12-15 · COPD
What this study did
NCT02766608 · Pearl Therapeutics, Inc.
2016-05-31 – 2017-12-01 · Chronic Obstructive Pulmonary Disorder
What this study did
NCT01602523 · Temple University
2011-03 – 2014-08 · Emphysema, Poor Sleep Quality
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT04331470 · Fasa University of Medical Sciences
2020-04-04 – 2020-05-20 · COVID-19
What this study did
Phase 2 (7)
Asthma
NCT06676319 · Sanofi
2024-11-07 – 2027-07-19 · Asthma
What this study did
NCT02573233 · Sanofi
2016-01-27 – 2018-01-03 · Asthma
What this study did
NCT02162784 · Intech Biopharm Ltd.
2013-02 – 2014-08 · Asthma
What this study did
Other / comorbidity
NCT01560689 · Assistance Publique - Hôpitaux de Paris
2008-06 – 2012-07 · Bronchiolitis Obliterans, Allogeneic Stem Cell Transplantation
What this study did
NCT00624754 · Assistance Publique - Hôpitaux de Paris
2008-03 – 2012-07 · Obstructive Airway Disease
What this study did
NCT00239278 · AstraZeneca
2001-01 – 2005-01 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 1/2 (3)
Asthma
NCT05111262 · Washington University School of Medicine
2021-12-16 – 2028-11-30 · Asthma, Nonadherence, Medication
What this study did
NCT05689983 · Washington University School of Medicine
2022-04-01 – 2025-09-25 · Asthma in Children, Nonadherence, Medication
What this study did
NCT00964535 · Orion Corporation, Orion Pharma
2009-09 – 2010-02 · Asthma
What this study did
Phase 1 (21)
Asthma
NCT07804303 · Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
2024-01-13 – 2024-01-24 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT03073057 · Orion Corporation, Orion Pharma
2016-01 – 2016-03 · Asthma
What this study did
NCT02237508 · Zambon SpA
2014-09 – 2015-02 · Asthma
What this study did
NCT02165033 · Intech Biopharm Ltd.
2012-11 – 2013-02 · Asthma
What this study did
NCT01668121 · Orion Corporation, Orion Pharma
2012-08 – 2012-11 · Asthma
What this study did
NCT01627158 · Orion Corporation, Orion Pharma
2012-06 – 2012-10 · Asthma
What this study did
NCT01593826 · Orion Corporation, Orion Pharma
2012-05 – 2012-10 · Asthma
What this study did
NCT01386996 · Orion Corporation, Orion Pharma
2011-07 – 2011-11 · Asthma
What this study did
NCT01423305 · Orion Corporation, Orion Pharma
2011-08 – 2011-10 · Asthma
What this study did
NCT01181063 · Orion Corporation, Orion Pharma
2010-08 – 2010-11 · Asthma
What this study did
Other / comorbidity
NCT06027606 · University of Alberta
2023-09-01 – 2025-09-25 · Healthy
What this study did
NCT06514157 · AstraZeneca
2024-08-19 – 2024-09-09 · Healthy Volunteer
What this study did
NCT03772223 · AstraZeneca
2019-01-21 – 2019-05-10 · Healthy Volunteers
What this study did
NCT03740373 · AstraZeneca
2018-09-04 – 2018-10-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01257048 · AstraZeneca
2011-08 – 2012-06 · COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation
What this study did
NCT00868426 · Orion Corporation, Orion Pharma
2009-04 – 2009-05 · Healthy
What this study did
Phase 4 (39)
Asthma
NCT07426458 · University of Miami
2026-04-27 – 2028-04 · Asthma
What this study did
Fasenra: An Asthma Studyenrolling by invitation
NCT07654842 · Endeavor Health
2026-07-01 – 2028-01-01 · Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
What this study did
NCT06568445 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2024-08-12 – 2027-09-30 · Bronchial Asthma
What this study did
NCT01225913 · Gelb, Arthur F., M.D.
2007-10 – 2027-06 · Asthma
What this study did
NCT06422689 · AstraZeneca
2024-05-10 – 2027-02-03 · Asthma
What this study did
NCT06590740 · AstraZeneca
2024-10-18 – 2025-09-03 · Cough-Variant Asthma
What this study did
NCT04171180 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-05-01 – 2023-05 · Cough Variant Asthma
What this study did
NCT03563001 · Zhujiang Hospital
2018-06-20 – 2018-09 · Pulmonary Disease, Chronic Obstructive, Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome, Small Airway Disease, Quality of Life
What this study did
NCT02934945 · Zhujiang Hospital
2015-09 – 2017-03 · Bronchial Asthma
What this study did
NCT02574975 · Zhujiang Hospital
2015-04 – 2016-05 · Asthma
What this study did
NCT00939341 · AstraZeneca
2009-07 – 2010-08 · Asthma
What this study did
NCT00997477 · Novartis Pharmaceuticals
2010-06 – 2010-07 · Asthma
What this study did
NCT00915538 · Western Sky Medical Research
2009-07 – 2009-08 · Asthma
What this study did
NCT00463866 · AstraZeneca
2007-03 – 2008-12 · Asthma
What this study did
NCT00272753 · AstraZeneca
2004-04 – 2005-11 · Asthma
What this study did
Other / comorbidity
NCT06905483 · Thammasat University
2025-04-01 – 2026-01-28 · COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple Therapy, Lung Function
What this study did
NCT05970263 · AstraZeneca
2024-01-19 – 2025-12-31 · COPD
What this study did
NCT06571942 · National Institute of Respiratory Diseases, Mexico
2023-11-15 – 2025-01-15 · COPD Bronchitis, Pollution Related Respiratory Disorder
What this study did
NCT02972476 · University of Dundee
2016-12 – 2019-07-22 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03551197 · Zhujiang Hospital
2018-06-13 – 2018-09 · Pulmonary Disease, Chronic Obstructive, Exercise, Lung Function Decreased, Quality of Life
What this study did
NCT03028701 · Neutec Ar-Ge San ve Tic A.Ş
2015-09 – 2017-03 · Copd
What this study did
NCT02533505 · AstraZeneca
2015-08-25 – 2016-08-12 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01794780 · Novartis Pharmaceuticals
2013-02-05 – 2015-05-25 · COPD
What this study did
NCT01769898 · The First Affiliated Hospital of Guangzhou Medical University
2013-07 – 2014-11 · Bronchiectasis
What this study did
NCT01397890 · AstraZeneca
2011-07 – 2013-06 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01415518 · AstraZeneca
2011-09-01 – 2012-12-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01760304 · Brigham and Women's Hospital
2012-01 – 2012-10 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01186653 · Hull University Teaching Hospitals NHS Trust
2007-10 – 2010-05 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00996697 · Brian J Lipworth
2006-10 – 2008-09 · COPD
What this study did
NCT00489853 · AstraZeneca
2007-07 – 2008-08 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00542880 · AstraZeneca
2007-09 – 2008-08 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00496470 · AstraZeneca
2007-05 – 2008-06 · Chronic Obstructive Pulmonary Disease, COPD
What this study did
NCT00379028 · AstraZeneca
2006-09 – 2007-07 · Chronic Obstructive Pulmonary Disease
What this study did
Early phase / not applicable (7)
Asthma
NCT07352488 · Henan University of Traditional Chinese Medicine
2026-01-15 – 2028-03-31 · Allergic Asthma
What this study did
NCT04203472 · Medical University of Warsaw
2019-01-20 – 2022-03-30 · Asthma, Cough Variant Asthma
What this study did
NCT02757209 · Consorzio Futuro in Ricerca
2016-04 – 2018-01 · Asthma, COPD
What this study did
NCT01117116 · National Jewish Health
2010-03 – 2013-09 · Asthma
What this study did
Other / comorbidity
NCT07595796 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-06-01 – 2028-02-29 · Preserved Ratio Impaired Spirometry (PRISM)
What this study did
NCT06597682 · Huashan Hospital
2025-03 – 2027-07 · Post-acute Sequelae of SARS-COV-2 Infection
What this study did
NCT03083067 · Peking University First Hospital
2017-03-20 – 2022-03-16 · COPD Exacerbation, Air Pollution
What this study did
Appears in other studies (53)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (10)
Other / comorbidity
NCT06596252 · Dr. Falk Pharma GmbH
2021-05-21 – 2028-03 · Eosinophilic Esophagitis
What this study did
NCT07383402 · Amin Javer
2026-03-30 – 2028-01-01 · Chronic Rhinosinusitis (CRS)
What this study did
NCT05878093 · Sanofi
2023-05-16 – 2024-11-28 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT04361474 · Fondation Ophtalmologique Adolphe de Rothschild
2020-05-18 – 2021-06-25 · Budesonide, Olfaction Disorders, SARS-CoV-2, Anosmia
What this study did
NCT02493335 · Dr. Falk Pharma GmbH
2016-01-15 – 2020-12-11 · Eosinophilic Esophagitis
What this study did
NCT03303677 · University of Florida
2018-04-01 – 2019-11-01 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT02668861 · The First Affiliated Hospital of Shanxi Medical University
2016-05 – 2017-05 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT02434029 · Dr. Falk Pharma GmbH
2015-11-11 – 2016-10-04 · Eosinophilic Esophagitis
What this study did
NCT01278082 · Dr. Falk Pharma GmbH
2008-04 – 2013-09 · Induction and Maintaining Remission of Collagenous Colitis
What this study did
NCT00747110 · Dr. Falk Pharma GmbH
2007-10 – 2010-08 · Colitis, Ulcerative
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT03519061 · Kaiser Permanente
2019-08-13 – 2019-10-01 · Chronic Sinus Infection, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinus Congestion
What this study did
NCT01857479 · Post Graduate Institute of Medical Education and Research, Chandigarh
2013-05 – 2015-06 · Allergic Bronchopulmonary Aspergillosis
What this study did
Phase 2 (9)
Other / comorbidity
NCT03803787 · Instituto Nacional de Cancerologia de Mexico
2018-09-01 – 2027-12-01 · Radiation Pneumonitis
What this study did
NCT06830109 · Washington University School of Medicine
2024-10-15 – 2026-12-30 · Nasal Obstruction
What this study did
NCT05214599 · Bazell Pharma AG
2021-04-23 – 2025-04 · Eosinophilic Esophagitis
What this study did
NCT03304626 · University of Cincinnati
2017-06-27 – 2019-12-31 · Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
What this study did
NCT02069847 · Mayo Clinic
2014-02 – 2019-01-11 · Esophageal Stricture
What this study did
NCT02862509 · Khon Kaen University
2015-11 – 2017-08 · Chronic Frontal Rhinosinusitis, Vertex to Floor Position
What this study did
NCT00767221 · Calliditas Therapeutics AB
2005-10 – 2008-11 · IGA Nephropathy
What this study did
NCT00940953 · Ligand Pharmaceuticals
2008-02 – 2008-05 · Seasonal Allergic Rhinitis
What this study did
NCT00135408 · Bristol-Myers Squibb
2005-12 – 2007-07 · Malignant Melanoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04964414 · Amanda Stapleton
2021-09-30 – 2023-03-29 · Dysosmia, Anosmia, Covid19
What this study did
Phase 1 (8)
Other / comorbidity
NCT07358234 · Mayo Clinic
2026-02-04 – 2027-12 · Eosinophilic Esophagitis (EoE)
What this study did
NCT07925216 · Triastek, lnc.
2026-11-03 – 2027-01 · IgA Nephropathy (IgAN)
What this study did
NCT07897240 · Triastek, lnc.
2026-10 – 2026-12 · IgA Nephropathy
What this study did
NCT07267130 · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
2025-11-25 – 2026-08-21 · Chronic Obstructive Pulmonary Disease
What this study did
NCT05519514 · Abbott
2021-07-12 – 2021-11-15 · Healthy Subjects, Human Volunteers, Healthy Participants, Bioequivalence
What this study did
NCT04080713 · Ferring Pharmaceuticals
2019-09-16 – 2019-09-25 · Healthy
What this study did
NCT03537326 · Parc de Salut Mar
2018-05-22 – 2018-09-10 · Healthy
What this study did
NCT01849406 · Ioannis Koutsourelakis
2013-04 – 2013-09 · Snoring
What this study did
Phase 4 (13)
Asthma
NCT00471809 · National Heart, Lung, and Blood Institute (NHLBI)
2006-03 – 2007-03 · Asthma
What this study did
Other / comorbidity
NCT06676384 · Christian Medical College, Vellore, India
2025-02-15 – 2029-08 · IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
What this study did
NCT06528015 · Gang Xu
2024-07 – 2028-12-31 · Glomerulonephritis, IGA, Probiotics, Budesonide
What this study did
NCT06076304 · Daniel Merenstein
2023-11-21 – 2028-12 · Sinus Infection, Acute Sinusitis
What this study did
NCT04342039 · University of British Columbia
2021-01-07 – 2027-12-31 · Epigenetic Effects of Intranasal Steroids, Environmental Exposure
What this study did
NCT06841406 · Universitaire Ziekenhuizen KU Leuven
2024-05-01 – 2026-12-31 · Functional Dyspepsia
What this study did
NCT06785662 · Siriraj Hospital
2025-02-12 – 2026-06-01 · Allergic Rhinitis
What this study did
NCT04132570 · Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
2019-10-22 – 2020-01-22 · Rhinitis
What this study did
NCT02409563 · Istituto per la Ricerca e l'Innovazione Biomedica
2014-01 – 2014-03 · Allergic Rhinitis
What this study did
NCT00912171 · University of Bologna
2009-01 – 2010-06 · Obstructive Sleep Apnea Syndrome
What this study did
Early phase / not applicable (10)
Asthma
NCT02318043 · Guangzhou Institute of Respiratory Disease
2007-01 – 2007-12 · Asthma
What this study did
Other / comorbidity
NCT07560462 · Shaare Zedek Medical Center
2026-05-01 – 2029-05-01 · Esophageal Stricture
What this study did
NCT07777796 · Silesian University of Medicine
2022-07-01 – 2026-07-30 · Chronic Cough (CC), Upper Airway Cough Syndrome, Chronic Rhinitis
What this study did
NCT06756243 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-03-01 – 2026-06-30 · Allergic Rhinitis
What this study did
NCT05541419 · Universidade Estadual de Londrina
2018-08-10 – 2025-08-10 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT06924190 · Lunan Better Pharmaceutical Co., LTD.
2024-12-30 – 2025-01-20 · Bioequivalence Study in Healthy Subjects
What this study did
NCT04952389 · Mayo Clinic
2021-12-07 – 2023-06-09 · Olfactory Dysfunction, COVID-19
What this study did
NCT04002349 · Beijing Tongren Hospital
2019-07-01 – 2020-03-31 · Determination of the Efficacy of Different Medications for Idiopathic Rhinitis, Impact of Different Medications on Biomarkers of Idiopathic Rhinitis, Safety and Tolerance of Different Medications for Idiopathic Rhinitis
What this study did
NCT02352168 · Guangzhou Institute of Respiratory Disease
2014-09 – 2015-10 · Allergic Rhinitis, Inflammation, Respiratory Tract Diseases, Hypersensitivity
What this study did
NCT01457716 · Orion Corporation, Orion Pharma
2011-10 – 2011-12 · Healthy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Budesonide (Pulmicort): this drugApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Desoximetasone (Topicort Spray)
Approved(overall)
Small moleculeGlucocorticoid receptor agonist
Partial signal(overall)
No reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race

Large race: only the 63 furthest-along competitors are listed; 25 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pulmicort (Budesonide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2Intubation ComplicationActive not recruiting
Est. primary completion 2026-12-30 · NCT03250975 · CT.gov ↗
What to watch
Early phase / not applicableRecessive Dystrophic Epidermolysis Bullosa, Dysphagia, Esophageal StenosisNot yet recruiting
Est. primary completion 2026-12-31 · NCT07684105 · CT.gov ↗
What to watch
2027 (3)
December 2027 (3)
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2027-12 · NCT06334575 · CT.gov ↗
What to watch
Phase 3Engraftment SyndromeRecruiting
Est. primary completion 2027-12-30 · NCT05509933 · CT.gov ↗
What to watch
Phase 2/3Crohn Disease (CD)Enrolling by invitation
Est. primary completion 2027-12-31 · NCT06719622 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Early phase / not applicableStridor, Larynx EdemaRecruiting
Est. primary completion 2028-02-25 · NCT05839756 · CT.gov ↗
What to watch
June 2028 (1)
Early phase / not applicableParoxysmal Atrial FibrillationRecruiting
Est. primary completion 2028-06 · NCT07877519 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableChronic Rhinosinusitis (CRS), Olfactory DysfunctionNot yet recruiting
Est. primary completion 2028-12-31 · NCT07386873 · CT.gov ↗
What to watch
2029 (3)
July 2029 (1)
Phase 3AsthmaNot yet recruiting
Est. primary completion 2029-07-30 · NCT07934420 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1/2Invasive Mechanical Ventilation, Severe Respiratory Distress SyndromeNot yet recruiting
Est. primary completion 2029-08 · NCT06855043 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Pneumonitis, Immune-related Adverse EventRecruiting
Est. primary completion 2029-12-01 · NCT06860542 · CT.gov ↗
What to watch

See the full readout calendar ↗